SLC5A2 and hydrops fetalis: In patients with T2DM and recent hospitalization for decompensated HF, sotagliflozin (an SGLT2 and SGLT1 inhibitor), initiated before or shortly after discharge, resulted in a significantly lower total number of deaths from CV causes and hospitalizations and urgent visits for HF than placebo (SOLOIST-WHF trial) [101].